NYXH
NyxoahNASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Key Statistics
Market Cap
$132.30M
P/E Ratio
—
EPS
$-2.73
Beta
0.87
52W High
$8.64
52W Low
$2.76
50-Day MA
$3.94
200-Day MA
$5.37
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Nyxoah
Nyxoah is a pioneering medical technology firm specializing in the treatment of obstructive sleep apnea (OSA) through its innovative Genio system, which employs a minimally invasive hypoglossal nerve stimulation technique. The company is dedicated to enhancing patient outcomes and quality of life for those affected by OSA, backed by a strong commitment to clinical validation and research excellence. Nyxoah's strategic emphasis on technology advancement, complemented by partnerships and extensive studies, not only positions it to address significant unmet needs in the sleep medicine market but also underscores its potential for sustainable growth and transformative contributions to the healthcare industry.
Fundamentals
| Revenue (TTM) | $10.02M |
| Gross Profit (TTM) | $6.33M |
| EBITDA | $-82.35M |
| Operating Margin | -329.30% |
| Return on Equity | -110.90% |
| Return on Assets | -37.70% |
| Revenue/Share (TTM) | $0.26 |
| Book Value | $1.33 |
| Price-to-Book | 2.72 |
| Price-to-Sales (TTM) | 13.20 |
| EV/Revenue | 12.5 |
| EV/EBITDA | -2.00 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 346.90% |
| Shares Outstanding | $43.66M |
| Float | $24.49M |
| % Insiders | 37.03% |
| % Institutions | 21.21% |
Analyst Ratings
Consensus ($10.86 target)
1
Strong Buy3
Buy1
HoldData last updated: 4/9/2026